Vimarsana
Biggest News Aggregation in the World

Direct Offering News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Direct Offering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Direct Offering Today - Breaking & Trending Today

Delaware Court of Chancery Agrees with SLC, Dismisses $1 Billion Suit Against Carvana | Morgan Lewis - Vimarsana News

Delaware Court of Chancery Agrees with SLC, Dismisses $1 Billion Suit Against Carvana | Morgan Lewis

In the case of Carvana Co. Stockholders Litigation, the Delaware Court of Chancery followed the special litigation committee’s (SLC’s) recommendation and dismissed a stockholder...

Nuvve Provides Fourth Quarter and Full Year 2023 Financial Update - Vimarsana News

Nuvve Provides Fourth Quarter and Full Year 2023 Financial Update

/PRNewswire/ -- Nuvve Holding Corp. (Nuvve) (Nasdaq: NVVE), a green energy technology company that provides a globally-available, commercial vehicle-to-grid...

FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum - Vimarsana News

FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum

/PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on...

FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum - Vimarsana News

FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum

HOUSTON, Feb. 20, 2024 /PRNewswire/ -- FibroBiologics is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential...

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - Vimarsana News

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED)...